Gyre Therapeutics Inc (GYRE)

Several events have impacted Gyre Therapeutics' stock price in the past six months. The stock declined after the Third Quarter 2025 financial results due to revised revenue guidance. The stock price increased after alignment with China's CDE on a conditional approval pathway and priority review eligibility for Hydronidone. Gyre Therapeutics entered into an agreement to acquire Cullgen Inc. The stock price decreased after the Fourth Quarter and Full Year 2025 financial results. The stock rose after China's NMPA granted Priority Review to the New Drug Application (NDA) for Hydronidone (F351). Gyre Therapeutics' subsidiary submitted the New Drug Application for F351 Hydronidone in China. Overall, the stock has experienced a -8.52% change over the past six months and a -12.14% change over the last year.

There is no specific information available indicating significant demand seasonality for Gyre Therapeutics, Inc.'s products and services. The company faces operational risks from rapid shifts in clinical demand and market conditions, which could impact its ability to adjust product offerings and production plans.

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing "fibrosis-first" therapies for chronic diseases. Their flagship product is ETUARY® (pirfenidone capsule), approved in China for idiopathic pulmonary fibrosis (IPF). They also commercialize Etorel® (nintedanib ethanesulfonate soft capsules) and Contiva® (avatrombopag maleate tablets) for other indications. Their pipeline includes Hydronidone (F351) for liver fibrosis, which has received Breakthrough Therapy designation in China, as well as other candidates for Acute-on-Chronic Liver Failure, Chronic Obstructive Pulmonary Disease, and Pulmonary Arterial Hypertension.

Gyre Therapeutics, Inc. is headquartered in San Diego, California, United States. They have a significant operational presence in the People's Republic of China through Gyre Pharmaceuticals Co., Ltd., with a sales and marketing team covering hospitals and pharmacies across 30 provinces, autonomous regions, and municipalities.

Gyre Therapeutics' brand reputation has been influenced by its clinical development progress and financial performance. Positive developments like successful Phase 3 trial results for Hydronidone and the Cullgen acquisition enhance its reputation. Underperforming the market and missing earnings estimates could be a concern for investors. The company's stock has also experienced some volatility, although its weekly volatility has been stable over the past year.

Gyre Therapeutics, Inc. has 45 institutional owners and shareholders holding a total of 3,344,739 shares. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and Geode Capital Management, Llc. Gni Group Ltd is the largest individual shareholder, owning 72.47% of the company. Other significant insider owners include Bvf Partners L P and Nea Partners 10 L P. Institutional shareholders hold 3.45% of the stock, while insiders hold 167.84%, and retail investors hold 0.00%.